ALMS Alumis Inc.
ALMS Alumis Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $7.18 · VWAP $17.53 · -65.1% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CFO, Officer + 4 others sold $394.3K, Aug 5
Coverage
1 watchlist
ALMS Price Structure
Loading timeframes…
Peers
Every watchlist ALMS belongs to, members best 30-day change first — ALMS highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-03-31: revenue $2M, diluted EPS $-0.74, net income $-93M (SEC filing). Across the print the stock moved -14.1% (close before → first close after).
full note →Against street estimates
How ALMS's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
ALMS research tape
28 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.